Excitation/Inhibition Modulators in Autism Spectrum Disorder: Current Clinical Research

Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by social and communication abnormalities. Heterogeneity in the expression and severity of the core and associated symptoms poses difficulties in classification and the overall clinical approach. Synaptic abnorma...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Roberto Canitano, Roberto Palumbi
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	children and adolescents autism spectrum disorders excitation/inhibition imbalance experimental treatments excitation/inhibition modulators Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/ce25c78f3c4b4b9f8cd8f48112a25b16
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ce25c78f3c4b4b9f8cd8f48112a25b16
record_format	dspace
spelling	oai:doaj.org-article:ce25c78f3c4b4b9f8cd8f48112a25b162021-12-01T18:28:25ZExcitation/Inhibition Modulators in Autism Spectrum Disorder: Current Clinical Research1662-453X10.3389/fnins.2021.753274https://doaj.org/article/ce25c78f3c4b4b9f8cd8f48112a25b162021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fnins.2021.753274/fullhttps://doaj.org/toc/1662-453XAutism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by social and communication abnormalities. Heterogeneity in the expression and severity of the core and associated symptoms poses difficulties in classification and the overall clinical approach. Synaptic abnormalities have been observed in preclinical ASD models. They are thought to play a major role in clinical functional abnormalities and might be modified by targeted interventions. An imbalance in excitatory to inhibitory neurotransmission (E/I imbalance), through altered glutamatergic and GABAergic neurotransmission, respectively, is thought to be implicated in the pathogenesis of ASD. Glutamatergic and GABAergic agents have been tested in clinical trials with encouraging results as to efficacy and tolerability. Further studies are needed to confirm the role of E/I modulators in the treatment of ASD and on the safety and efficacy of the current agents.Roberto CanitanoRoberto PalumbiFrontiers Media S.A.articlechildren and adolescentsautism spectrum disordersexcitation/inhibition imbalanceexperimental treatmentsexcitation/inhibition modulatorsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENFrontiers in Neuroscience, Vol 15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	children and adolescents autism spectrum disorders excitation/inhibition imbalance experimental treatments excitation/inhibition modulators Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	children and adolescents autism spectrum disorders excitation/inhibition imbalance experimental treatments excitation/inhibition modulators Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Roberto Canitano Roberto Palumbi Excitation/Inhibition Modulators in Autism Spectrum Disorder: Current Clinical Research
description	Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by social and communication abnormalities. Heterogeneity in the expression and severity of the core and associated symptoms poses difficulties in classification and the overall clinical approach. Synaptic abnormalities have been observed in preclinical ASD models. They are thought to play a major role in clinical functional abnormalities and might be modified by targeted interventions. An imbalance in excitatory to inhibitory neurotransmission (E/I imbalance), through altered glutamatergic and GABAergic neurotransmission, respectively, is thought to be implicated in the pathogenesis of ASD. Glutamatergic and GABAergic agents have been tested in clinical trials with encouraging results as to efficacy and tolerability. Further studies are needed to confirm the role of E/I modulators in the treatment of ASD and on the safety and efficacy of the current agents.
format	article
author	Roberto Canitano Roberto Palumbi
author_facet	Roberto Canitano Roberto Palumbi
author_sort	Roberto Canitano
title	Excitation/Inhibition Modulators in Autism Spectrum Disorder: Current Clinical Research
title_short	Excitation/Inhibition Modulators in Autism Spectrum Disorder: Current Clinical Research
title_full	Excitation/Inhibition Modulators in Autism Spectrum Disorder: Current Clinical Research
title_fullStr	Excitation/Inhibition Modulators in Autism Spectrum Disorder: Current Clinical Research
title_full_unstemmed	Excitation/Inhibition Modulators in Autism Spectrum Disorder: Current Clinical Research
title_sort	excitation/inhibition modulators in autism spectrum disorder: current clinical research
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/ce25c78f3c4b4b9f8cd8f48112a25b16
work_keys_str_mv	AT robertocanitano excitationinhibitionmodulatorsinautismspectrumdisordercurrentclinicalresearch AT robertopalumbi excitationinhibitionmodulatorsinautismspectrumdisordercurrentclinicalresearch
_version_	1718404721435213824

Excitation/Inhibition Modulators in Autism Spectrum Disorder: Current Clinical Research

Ejemplares similares